First-in-human study assessing safety and tolerability of REGN1979, a novel CD20xCD3 bispecific antibody, in patients with CD20+B-cell malignancies previously treated with anti-CD20 therapy. Brownstein, C. M., Adriaens, L., Bannerji, R., Chavez, J. C., Levy, R., Ansell, S., Advani, R. H., Patel, S., Kostic, A., Trail, P., Lowy, I., Kohrt, H. AMER SOC CLINICAL ONCOLOGY. 2015

View details for Web of Science ID 000358036904705